Limitations of current monoclonal antibodies for plaque-type psoriasis and an outlook for the future

References

• Baker C, Mack A, Cooper A, et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J Dermatol. 2013;54:148–154.
   PubMed Web of Science ®Google Scholar
• Golden JB, McCormick TS, Ward NL. IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine. 2013;62:195–201.
   PubMed Web of Science ®Google Scholar
• Vilarrasa E, Notario J, Bordas X, et al. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): a retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol. 2016;74:1066–1072.
   PubMed Web of Science ®Google Scholar
• de Carvalho AV, Duquia RP, Horta BL, et al. Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: a systematic review and meta-analysis of randomized clinical trials. Drugs R D. 2017;17:29–51.
   PubMed Web of Science ®Google Scholar
• Lambert J, Nast A, Nestle FO, et al. Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: what can be learnt from other diseases? J Dermatol Treat. 2015;26:520–527.
   PubMed Web of Science ®Google Scholar
• Ara-Martín M, Pinto PH, Pascual-Salcedo D. Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study. J Dermatolog Treat. 2017;8:1–7.
   Google Scholar
• Balato A, Scala E, Balato N, et al. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders. Expert Opin Biol Ther. 2017;17:1363–1374.
   PubMed Web of Science ®Google Scholar
• Talamonti M, D’Adamio S, Bianchi L, et al. The role of pharmacogenetics in chronic plaque psoriasis: update of the literature. Mol Diagn Ther. 2017;21:467–480.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75:83–98.e4.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371:326–338.
   PubMed Web of Science ®Google Scholar
• Egeberg A. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:2101–2102.
   PubMedGoogle Scholar
• Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177:1014–1023.
   PubMed Web of Science ®Google Scholar
• Menter A, Warren RB, Langley RG, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017;31:1686–1692.
   PubMed Web of Science ®Google Scholar
• Ramaekers BLT, Wolff RF, Pouwels X, et al. Ixekizumab for treating moderate-to-severe plaque psoriasis: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018 [Epub ahead of print].
   Google Scholar
• Blauvelt A, Gooderham M, Iversen L, et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017;77:855–862.
   PubMed Web of Science ®Google Scholar
• Megna M, Balato A, Raimondo A, et al. Guselkumab for the treatment of psoriasis. Expert Opin Biol Ther. 2018;18:459–468.
   PubMed Web of Science ®Google Scholar
• Spindeldreher S, Maillère B, Correia E, et al. Secukinumab demonstrates significantly lower immunogenicity potential compared to ixekizumab. Dermatol Ther (Heidelb). 2018;8:57–68.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Raimondo A, Lembo S, et al. Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol. 2016;12:1299–1308.
   PubMed Web of Science ®Google Scholar
• Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:1035–1050.
   PubMed Web of Science ®Google Scholar
• Spandonaro F, Ayala F, Berardesca E, et al. The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy. BioDrugs. 2014;28:285–295.
   PubMed Web of Science ®Google Scholar
• Cheng J, Feldman SR. The cost of biologics for psoriasis is increasing. Drugs Context. 2014;3:212266.
   PubMedGoogle Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583–1590.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Thaçi D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176:928–938.
   PubMed Web of Science ®Google Scholar
• Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76:1093–1102.
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Olsen IC, Goll GL, et al. NOR-SWITCH study group. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304–2316.
   PubMed Web of Science ®Google Scholar